Vijaya Diagnostic Centre Ltd
Vijaya Diagnostic Centre Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets a 15% compound annual growth rate (CAGR) over the next 3 years. The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
From Vijaya Diagnostic Centre Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a 15% compound annual growth rate (CAGR) over the next 3 years.
- Expected volume growth is around 13% per year, with the remaining revenue growth attributed to value or realization growth of approximately 2%.
- Growth outlook includes significant hub expansion: 12 hubs planned over 1.5 years, including new geographies like Bangalore, Pune, and Kolkata.
- New hubs are expected to take about 1 year to achieve EBITDA breakeven.
- Market share gains are expected in core geographies (Andhra Pradesh and Telangana) due to brand strength, dense network, and advanced technology.
2 more points from Vijaya Diagnostic Centre Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vijaya Diagnostic Centre Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26.
- This INR 200 crores capex includes renovation and addition of extra MRI at Kurnool.
- Additional two hub centers in Andhra Pradesh and Telangana are planned, with leases under finalization, expected by Q3 FY '26.
- Capex plans remain materially unchanged despite new hubs and PET-CT machine in Tirupathi.
- PET-CT at Tirupathi is on a pay-per-use model, thus not part of capex.
- Focus on strategic expansion across Bangalore, Pune, Kolkata, and adjacent geographies.
2 more points from Vijaya Diagnostic Centre Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vijaya Diagnostic Centre Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Vijaya Diagnostic Centre Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹219 Cr, net profit ₹48 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vijaya Diagnostic Centre Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio DX Ltd (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Syngene International Ltd (Q3 FY25)
Q3 FY'25 showed an 11% revenue growth after two quarters of decline, indicating a return to growth momentum. Key concall takeaways from Syngene International…
Arthneeti Pro · Annual
Vijaya Diagnostic Centre Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vijaya Diagnostic Centre Ltd Q3 FY25 results?
The company targets a 15% compound annual growth rate (CAGR) over the next 3 years. The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
What is Vijaya Diagnostic Centre Ltd share price analysis?
Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vijaya Diagnostic Centre Ltd planning capital expenditure?
The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26.
Keep Vijaya Diagnostic Centre Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.